Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Completion of a Trial Protocol to Study its Self Assembling Vaccine to Target Prostate Stem Cell Antigen

2025-07-24T17:06:09-04:00

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces [...]

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Completion of a Trial Protocol to Study its Self Assembling Vaccine to Target Prostate Stem Cell Antigen2025-07-24T17:06:09-04:00

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Sponsored Research Agreement with the Massachusetts General Hospital, Harvard Medical School, to Initiate a Pre-clinical Immuno-Oncology Trial

2023-08-25T14:20:35-04:00

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces [...]

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Sponsored Research Agreement with the Massachusetts General Hospital, Harvard Medical School, to Initiate a Pre-clinical Immuno-Oncology Trial2023-08-25T14:20:35-04:00

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge Study

2023-04-05T20:03:51-04:00

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, [...]

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge Study2023-04-05T20:03:51-04:00
Copyright 2022 Voltron, Inc. | All Rights Reserved.
Go to Top